688068.SH
热景生物
SSE · Healthcare · Biotechnology · CN
CNY 99.29
−6.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 427.7M | 404.9M | 509.8M | 547.8M | 3.6B |
| Cost of Revenue | 172.5M | 171.8M | 226.8M | 234.9M | 1.6B |
| Gross Profit | 255.1M | 233.1M | 283.0M | 313.0M | 1.9B |
| Operating Expenses | |||||
| R&D Expense | 190.5M | 162.3M | 166.1M | 132.9M | 191.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 107.7M | 108.1M | 108.9M | 91.7M | 214.7M |
| Selling & Marketing Expense | 248.7M | 220.6M | 191.6M | 171.7M | 268.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 552.5M | 486.6M | 442.6M | 358.2M | 651.2M |
| Cost and Expenses | 725.0M | 658.4M | 669.4M | 593.1M | 2.3B |
| Operating Income (EBIT) | (304.0M) | (264.9M) | (223.1M) | 18.7M | 1.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (306.7M) | (267.3M) | (225.4M) | 15.0M | 1.1B |
| Income Tax Expense | (9.2M) | (8.6M) | 8.1M | (1.7M) | 150.1M |
| Bottom Line | |||||
| Net Income | (246.7M) | (216.0M) | (205.8M) | 28.9M | 944.7M |
| Earnings from Cont. Ops | (297.6M) | (258.6M) | (233.5M) | 16.7M | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (246.7M) | (216.0M) | (205.8M) | 28.9M | 944.7M |
| Per Share | |||||
| Basic EPS | (CN¥2.81) | (CN¥2.50) | (CN¥2.36) | CN¥0.33 | CN¥10.33 |
| Diluted EPS | (CN¥2.81) | (CN¥2.50) | (CN¥2.36) | CN¥0.32 | CN¥10.28 |
| Revenue Per Share | CN¥4.84 | CN¥4.69 | CN¥5.85 | CN¥6.25 | CN¥38.89 |
| Shares | |||||
| Basic Shares Outstanding | 88.4M | 86.4M | 87.2M | 87.6M | 91.5M |
| Diluted Shares Outstanding | 88.4M | 86.4M | 87.2M | 87.6M | 91.5M |
| Profitability Metrics | |||||
| EBITDA | — | (176.1M) | (121.2M) | 87.7M | 1.2B |
| D&A | — | 88.8M | 101.9M | 69.0M | 117.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026